Perfromance Wealth Partners LLC Sells 1,200 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Perfromance Wealth Partners LLC lowered its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 41.0% in the fourth quarter, HoldingsChannel reports. The fund owned 1,726 shares of the biotechnology company’s stock after selling 1,200 shares during the period. Perfromance Wealth Partners LLC’s holdings in Sarepta Therapeutics were worth $210,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in SRPT. American Century Companies Inc. raised its position in shares of Sarepta Therapeutics by 14.1% during the second quarter. American Century Companies Inc. now owns 7,184 shares of the biotechnology company’s stock worth $1,135,000 after acquiring an additional 889 shares during the last quarter. Envestnet Asset Management Inc. raised its position in shares of Sarepta Therapeutics by 69.1% during the second quarter. Envestnet Asset Management Inc. now owns 68,679 shares of the biotechnology company’s stock worth $10,851,000 after acquiring an additional 28,073 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Sarepta Therapeutics by 13.9% during the second quarter. Dimensional Fund Advisors LP now owns 255,396 shares of the biotechnology company’s stock worth $40,353,000 after acquiring an additional 31,105 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its position in shares of Sarepta Therapeutics by 40.8% during the second quarter. Mercer Global Advisors Inc. ADV now owns 5,621 shares of the biotechnology company’s stock worth $888,000 after acquiring an additional 1,630 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its position in shares of Sarepta Therapeutics by 11.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 4,505 shares of the biotechnology company’s stock worth $712,000 after acquiring an additional 479 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $116.79 on Wednesday. Sarepta Therapeutics, Inc. has a one year low of $102.15 and a one year high of $173.25. The firm has a market cap of $11.16 billion, a price-to-earnings ratio of 93.43 and a beta of 0.77. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock’s 50-day moving average is $121.66 and its 200-day moving average is $128.87.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on SRPT shares. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. Evercore ISI decreased their price objective on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. HC Wainwright reaffirmed a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, January 15th. Piper Sandler decreased their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Finally, Jefferies Financial Group started coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They set a “buy” rating and a $165.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $178.71.

Insider Buying and Selling

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.